Business
Hemogenyx Pharmaceuticals PLC Announces Grant of Options and Extension of Warrant Term
Hemogenyx Pharmaceuticals PLC Announces Grant of Options and Extension of Warrant
About this update from Hemogenyx Pharmaceuticals Plc
[{"type":"text","content":"THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION AS STIPULATED UNDER THE UK VERSION OF THE MARKET ABUSE REGULATION NO 596/2014 WHICH IS PART OF ENGLISH LAW BY VIRTUE OF THE EUROPEAN (WITHDRAWAL) ACT 2018, AS AMENDED. ON PUBLICATION OF THIS ANNOUNCEMENT VIA A REGULATORY INFORMATION SERVICE, THIS INFORMATION IS CONSIDERED TO BE IN THE PUBLIC DOMAIN.Grant of Options and Extension of Warrant TermLONDON, UK / ACCESS Newswire / May 29, 2026 / Hemogenyx Pharmaceuticals plc (LSE:HEMO), a clinical-stage biopharmaceutical group focused on developing treatments for cancers and viral diseases, announces the grant of share options and a variation to the exercise period for certain investor warrants.Grant of Share OptionsThe Board of Directors has agreed to grant options over a total of 1,200,000 ordinary shares of 1p each in the capital of the Company (\"Board Share Options\") to the Company's Non-Executive Directors Peter Redmond, Alexis Sandler, Sir Marc Feldmann (Chairman) and Executive Director Vladislav Sandler (CEO).The details of the Board Share Options granted are set out below:NamePositionNumber of Share Options GrantedExercise Price (pounds)Expiry DatePeter RedmondNon-executive Director300,0008.029 May 2031Sir Marc FeldmannNon-executive Chairman300,0008.029 May 2031Vladislav SandlerCEO300,0008.029 May 2031Alexis SandlerNon-executive Director300,0008.029 May 2031Koen Van BesienMedical Director60,0008.029 May 2031Further, options have been granted to employees over a total of 60,000 ordinary shares of 1p each in the capital of the Company (\"Employee Share Options\"). The Employee Share Options will have an exercise price of £8 and expire on 29 May 2031.The Board and Employee Share Options will vest immediately.Following the grant of the Board and Employee Share Options there are, in aggregate, 1,410,479 ordinary shares of 1p each in the Company under option held by directors, employees and members of the Scientific Advisory Board of the Company, representing 20.7% of the issued ordinary share capital of the Company.Extension to warrant exercise periodThe Company has extended the term of 69,048 warrants granted to a group of investors to 7 September 2026 (the \"Warrants\"). The Warrants were originally granted to the investors on 8 March 2025 with a term of fifteen months.The Board has concluded that the term of the Warrants should be e...